Melissa B. Epperly, Chief Financial Officer at Zentalis Pharmaceuticals, Inc. (ZNTL), sold 5,155 shares at $60.14 ($307K) on 2021-05-03, disclosed to the SEC on 2021-05-05.
Open-market sale of $307k ZNTL by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $56.99 | 350 | $20K | 6.5% |
| 2 | $58.04 | 661 | $38K | 12.5% |
| 3 | $59.83 | 950 | $57K | 18.5% |
| 4 | $59.83 | 950 | $57K | 18.5% |
| 5 | $60.14 | 1,122 | $67K | 22.0% |
| 6 | $60.14 | 1,122 |
| $67K |
| 22.0% |
| Total | $59.54 avg | 5,155 | $307K | 100% |
| Filing → |
| ROIV | SELL | 2026-07-01 | $610K | — | Filing → |
| ROIV | SELL | 2026-03-18 | $1.2M | — | Filing → |
| ZNTL | SELL | 2024-02-12 | $29K | — | Filing → |